.png&w=3840&q=75)
The Chinese Antibody Society (ChAbS), a global professional organization dedicated to advancing antibody-based therapeutics, has closed a Series B funding round, bringing in $101.0M. The capital infusion will support its mission to foster collaboration across the discovery, development, manufacturing, and marketing of therapeutic antibodies.
As an independent non-profit, non-government society, ChAbS connects industry, academics, healthcare providers, and investors. It serves as a nurturing platform for interaction and networking among its worldwide members, and also publishes its official journal, Antibody Therapeutics, in collaboration with Oxford University Press.
